News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Dynavax (DVAX) Intrexon (XON) Ocular Therapeutix (OCUL) Auspex (ASPX) NEKTAR (NKTR)) Bristol-Myers Squibb (BMY) Human Longevity (HLI) Biocryst (BCRX) SERES THERAPEUTICS (MCRB) Xoma (XOMA) Valeant Pharmaceuticals International (VRX) Global Cell Therapeutics (GBT) Adaptimmune (ADAP) Ionis (IONS) Mirati Therapeutics (MRTX) Amgen (AMGN) Prosensa (RNA) ARGOS (ARGS) Prolor Biotech (PBTH) PTC Therapeutics (PTCT) GUARDIAN HEALTH Illumina (ILMN) VANDA (VNDA) Zerenex Alder Biopharmaceuticals (ALDR) KERYX (KERX) Elan (ELN) OSI (OSIP) JOUNCE THERAPEUTICS (JNCE) IDERA (IDRA) AERIE PHARMACEUTICALS Agenus (AGEN C4 Therapeutics SUNESIS PHARMACEUTICALS (SNSS) HALOZYME (HALO) Galena (GALE) Rapamune Idenix (IDIX) Sanofi-Aventis (SAN) Incyte (INCY) Roche (RHHBY) Spike Therapeutics (ONCE) Intercept (ICPT) Trastuzumab-DM1 NANTKWEST (NK) Alnylam (ALNY) ZALTRAP™ Aimmune Therapeutics (AIMT) BIOMARIN (BMRN) Ridaforolimus ADVENTRIX (ANX) Ziofpharm (ZIOP) ARCA (ABIO) ABBVIE (ABBV) PORTOLA (PTLA) Advaxis (ADXS) ACADIA (ACAD) Velcade (bortezomib) Roche (ROCHE) AstraZeneca (AZN) Gilead (GILD) Merck (MRK) Exelixis (EXEL) NOVOCURE (NVCR) TOKAI (TKAOI) Ariad (ARIA) Endometrial Cancer GlaxoSmithKline (GSK) REGULUS (RGLS) Human Genome Sciences (HGSI) MODERNA Sanofi (SNA) Theravance Bio Pharma (TBPH) Revlimid (lenolidamide) Dendreon (DNDN) Array Pharmaceuticals (ARRY) Biogen Idec (BIIB) Jazz Pharmaceuticals (JAZZ) Abbott Laboratories (ABT) ImmunoGen (IMGN) Pluristem (PSTI) Sanofi (SNY) Multiple Myeloma ISIS (ISIS) Regeneron (REGN) JUNO (JUNO) Agenus (AGEN) Micromet (MITI) Vertex (VRTX) RenenxBio (RGNX) Vitae Pharmaceuticals (VTAE) Anadys (ANDS) Genentech Telaprevir AGOS (ARGS) CompuGen (CGEN) Sangamo (SGMO) Sarepta (SRPT) Intermune (ITMN) SYNTA (SNTA) Bellicum (BLCM) KITE (KITE) CEMPRA (CEMP) INNOVIVA (INVA) Seattle Genetics (SGEN) Benlysta (belimumab) Editas (EDIT) CRISPR Therapeutics (CRSP) Onyx (ONXX) Herceptin Anacor (ANAC) galapagos (GLPG) Tysabri Cytokinetics (CYTK) Sequenom (SQNM) Theravance (THRX) Inovio (INO)